Evaluating Weight of Evidence in the Mystery of Balkan Endemic Nephropathy

Risk Analysis

Volumn 34, Issue 9, 2014, Pages 1688-1705

  Bui Klimke, Travis ^a   Wu, Felicia ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b Michigan State University   (United States)

Author keywords

Aristolochic acid; Balkan endemic nephropathy; Bradford Hill criteria; Ochratoxin A; Weight of evidence

Indexed keywords

ASCORBIC ACID; GRAIN (AGRICULTURAL PRODUCT); TOXIC MATERIALS; VIRUSES;

ARISTOLOCHIC ACID; BRADFORD HILL CRITERIA; NEPHROPATHY; OCHRATOXIN A; WEIGHT OF EVIDENCES;

PATHOLOGY;

ARISTOLOCHIA; TRITICUM AESTIVUM;

BALKAN NEPHROPATHY; EVIDENCE BASED MEDICINE; HUMAN;

BALKAN NEPHROPATHY; EVIDENCE-BASED MEDICINE; HUMANS;

EID: 84939261794     PISSN: 02724332     EISSN: 15396924     Source Type: Journal    
DOI: 10.1111/risa.12239     Document Type: Article

References (158)

1. Polenakovic M, Stefanovic V. Balkan nephropathy. Pp. 857-866 in Cameron JS, Davison AM, Grunfeld JP, Kerr D, Ritz E. (eds). Oxford Textbook of Clinical Nephrology, 1st ed. Oxford, UK: Oxford University Press, 1992.
2. Craciun EC, Rosculescu I. On Danubian endemic familial nephropathy (Balkan nephropathy). Some problems. American Journal of Medicine, 1970; 49(6):774-779.
3. Tanchev I, Ts E, Dorosiev D, Zh P, Tsvetkov G. [Study of nephritis in Vrattsa district]. Suvremenna Meditsina (Sofiia), 1956; 7(9):14-29.
4. Batuman V. Fifty years of Balkan endemic nephropathy: Daunting questions, elusive answers. Kidney International, 2006; 69(4):644-646.
5. Grollman AP, Shibutani S, Moriya M, Miller F, Wu L, Moll U, Suzuki N, Fernandes A, Rosenquist T, Medverec Z, Jakovina K, Brdar B, Slade N, Turesky RJ, Goodenough AK, Rieger R, Vukelic M, Jelakovic B. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proceedings of the National Academy of Sciences of the United States of America, 2007; 104(29):12129-12134.
6. Tatu CA, Orem WH, Finkelman RB, Feder GL. The etiology of Balkan endemic nephropathy: Still more questions than answers. Environmental Health Perspectives, 1998; 106(11):689-700.
7. Pfohl-Leszkowicz A, Manderville RA. Ochratoxin A: An overview on toxicity and carcinogenicity in animals and humans. Molecular Nutrition & Food Research, 2007; 51(1):61-99.
8. Stefanovic V, Radovanovic Z. Balkan endemic nephropathy and associated urothelial cancer. Nature Clinical Practice Urology, 2008; 5(2):105-112.
9. Radovanovic Z. Topographical distribution of Balkan endemic nephropathy in Serbia (Yugoslavia). Tropical and Geographical Medicine, 1979; 31(2):185-189.
10. Cukuranovic R, Petrovic B, Cukuranovic Z, Stefanovic V. Balkan endemic nephropathy: A decreasing incidence of the disease. Pathologie Biologie (Paris), 2000; 48(6):558-561.
11. Bukvic D, Maric I, Arsenovic A, Jankovic S, Djukanovic L. Prevalence of Balkan endemic nephropathy has not changed since 1971 in the Kolubara region in Serbia. Kidney and Blood Pressure Research, 2007; 30(2):117-123.
12. Bukvic D, Jankovic S, Arsenovic A, Djukanovic L. Balkan endemic nephropathy is still present in the Kolubara region, Serbia. Renal Failure, 2005; 27(5):565-569.
13. Cvitkovic A, Vukovic-Lela I, Edwards KL, Karanovic S, Juric D, Cvoriscec D, Fucek M, Jelakovic B. Could disappearance of endemic (Balkan) nephropathy be expected in forthcoming decades? Kidney and Blood Pressure Research, 2011; 35(3):147-152.
14. Wedeen RP. Environmental renal disease: Lead, cadmium and Balkan endemic nephropathy. Kidney International Supplements, 1991; 34:S4-8.
15. Maksimovic ZJ, Djujic I. Selenium deficiency in Serbia and possible effects on health. Biomedical and Environmental Sciences, 1997; 10(2-3):300-306.
16. Maksimovic ZJ, Djujic I, Jovic V, Rsumovic M. Selenium deficiency in Yugoslavia. Biological Trace Element Research, 1992; 33:187-196.
17. Pfohl-Leszkowicz A, Petkova-Bocharova T, Chernozemsky IN, Castegnaro M. Balkan endemic nephropathy and associated urinary tract tumours: A review on aetiological causes and the potential role of mycotoxins. Food Additives & Contaminants, 2002; 19(3):282-302.
18. Long DT, Voice TC. Role of exposure analysis in solving the mystery of Balkan endemic nephropathy. Croatian Medical Journal, 2007; 48(3):300-311.
19. Nichifor E, Balea M, Rusu G, Melencu M, Ghiordanescu N, Cristescu I, Dovlete C, Sonoc S. Studies on the familial character of endemic Balkan nephropathy. Possible role of the toxic hydric factor in the determination of "familial agglomerations" in endemic Balkan nephropathy. Médecine Interne, 1985; 23(3):229-237.
20. Markovic B, Lebedev S, Djordjevic M, Arambasic M. Endemic urinary tract cancer in Bulgaria, Yugoslavia, and Romania: Etiology and pathogenesis. Medicine, Biology & Environment, 1976; 4:1-2.
21. Georgescu L, Diosi P. Virus-like particles in the kidneys of three patients with endemic Balkan nephropathy. Virologie, 1981; 32(4):305-306.
22. Apostolov K, Spasic P. Evidence of a viral aetiology in endemic (Balkan) nephropathy. Lancet, 1975; 2(7948):1271-1273.
23. Stoian M, Hozoc M, Iosipenco M, Nastac E, Melencu M. Serum antibodies to papova viruses (bk and sv 40) in subjects from the area with Balkan endemic nephropathy. Virologie, 1983; 34(2):113-117.
24. Shindarov L, Tonev E. Cultivation of vaccinia virus in tissue culture from the liver of a cold-blooded animal (lacerta viridis). Acta Virologica, 1965; 9(5):459-461.
25. Radovanovic Z. Epidemiological evidence on Balkan nephropathy as a viral disease. Medical Hypotheses, 1987; 22(2):171-175.
26. Pasare G, Pasare V, Melencu M. The role of environmental pollution in the etiology of endemic nephropathy. Sante Publique (Bucur), 1975; 18(1):65-71.
27. Dotchev D, Popov N, Neychev S. Screening tests for bacteriuria in patients with endemic nephropathy. Endemic Nephropathy. Pp. 84-85 in Proceedings of the Second International Symposium on Endemic Nephropathy (9-12 November 1972) Sofia, Bulgaria: Publishing House of the Bulgarian Academy of Science, 1974.
28. Voice TC, Long DT, Radovanovic Z, Atkins JL, McElmurry SP, Niagolova ND, Dimitrov P, Petropoulos EA, Ganev VS. Critical evaluation of environmental exposure agents suspected in the etiology of Balkan endemic nephropathy. International Journal of Occupational and Environmental Health, 2006; 12(4):369-376.
29. Feder GL, Radovanovic Z, Finkelman RB. Relationship between weathered coal deposits and the etiology of Balkan endemic nephropathy. Kidney International Supplements, 1991; 34:S9-S11.
30. Goldberg MC, Feder GL, Radovanovic Z. Correlation of Balkan endemic nephropathy with fluorescent organic compounds in shallow groundwater. Hydrogeology Journal, 1994; 2(4):15-22.
31. Orem WH, Feder GL, Finkelman RB. A possible link between Balkan endemic nephropathy and the leaching of toxic organic compounds from Pliocene lignite by groundwater: Preliminary investigation. International Journal of Coal Geology, 1999; 40(2-3):237-252.
32. Orem WH, Tatu CA, Feder GL, Finkelman RB, Lerch HE, Maharaj SVM, Szilagyi D, Dumitrascu V, Paunescu V, Margineanu F. Environment, geochemistry and the etiology of Balkan endemic nephropathy: Lessons from Romania. Facta Universitatis-Series: Architecture and Civil Engineering, 2002; 9(1):39-48.
33. Voice TC, McElmurry SP, Long DT, Dimitrov P, Ganev VS, Peptropoulos EA. Evaluation of the hypothesis that Balkan endemic nephropathy is caused by drinking water exposure to contaminants leaching from Pliocene coal deposits. Journal of Exposure Science and Environmental Epidemiology, 2006; 16(6):515-524.
34. Toncheva D, Dimitrov T. Genetic predisposition to Balkan endemic nephropathy. Nephron, 1996; 72(4):564-569.
35. Toncheva D, Dimitrov T, Tzoneva M. Cytogenetic studies in Balkan endemic nephropathy. Nephron, 1988; 48(1):18-21.
36. Toncheva DI, Gergov TD, Tzoneva MT, Bouchakliev ZP. Spontaneous and induced chromosome aberrations in Balkan endemic nephropathy. Kidney International Supplements, 1991; 34:S97-S101.
37. JECFA (Joint Expert Committee on Food Additives). Ochratoxin A. Pp. 281-415 in Safety Evaluation of Certain Mycotoxins in Food: Prepared by the 56th Meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA) (WHO Food Additives Series, No. 47). Geneva: World Health Organization, 2001.
38. Krogh P. Mycotoxic porcine neprophathy: A possible model for Balkan endemic nephropathy. Pp. 266-270 in Puhlev, A (ed), Endemic Nephropathy. Sofia: Publishing House of the Bulgarian Academy of Science, 1974.
39. Duarte SC, Pena A, Lino CM. Human ochratoxin A biomarkers-From exposure to effect. Critical Reviews in Toxicology, 2011; 41(3):187-212.
40. Kuiper-Goodman T, Scott PM. Risk assessment of the mycotoxin ochratoxin A. Biomedical and Environmental Sciences, 1989; 2:179-248.
41. Huff JE. Carcinogenicity of ochratoxin A in experimental animals. IARC Scientific Publication Series, 1991; 115:229-244.
42. Kuiper-Goodman T. Risk assessment of ochratoxin A residues in food. IARC Scientific Publication, 1991; 115:307-320.
43. JECFA. Ochratoxin A. Pp. 357-429 in Safety Evaluation of Certain Mycotoxins in Food: Prepared by the 68th Meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA) (WHO Food Additives Series, No. 59). Geneva: World Health Organization, 2008.
44. Walker R, Larsen JC. Ochratoxin A: Previous risk assessments and issues arising. Food Additives & Contaminants, 2005; 22 (Suppl 1):6-9.
45. Pfohl-Leszkowicz A, Tozlovanu M, Manderville R, Peraica M, Castegnaro M, Stefanovic V. New molecular and field evidences for the implication of mycotoxins but not aristolochic acid in human nephropathy and urinary tract tumor. Molecular Nutrition & Food Research, 2007; 51(9):1131-1146.
46. Mally A, Zepnik H, Wanek P, Eder E, Dingley K, Ihmels H, Volkel W, Dekant W. Ochratoxin A: Lack of formation of covalent DNA adducts. Chemical Research in Toxicology, 2004; 17(2):234-242.
47. Krogh P, Hald B, Plestina R, Ceovic S. Balkan (endemic) nephropathy and foodborne ochratoxin A: Preliminary results of a survey of foodstuffs. Acta Pathologica Microbiologica Scandinavica Series B, 1977; 85(3):238-240.
48. Pavlovic M, Plestina R, Krogh P. Ochratoxin A contamination of foodstuffs in an area with Balkan (endemic) nephropathy. Acta Pathologica Microbiologica Scandinavica Series B, 1979; 87(4):243-246.
49. Petkova-Bocharova T, Castegnaro M. Ochratoxin A contamination of cereals in an area of high incidence of Balkan endemic nephropathy in Bulgaria. Food Additives & Contaminants, 1985; 2(4):267-270.
50. Petkova-Bocharova T, Chernozemsky IN, Castegnaro M. Ochratoxin A in human blood in relation to Balkan endemic nephropathy and urinary system tumours in Bulgaria. Food Additives & Contaminants, 1988; 5(3):299-301.
51. Petkova-Bocharova T, Castegnaro M, Michelon J, Maru V. Ochratoxin A and other mycotoxins in cereals from an area of Balkan endemic nephropathy and urinary tract tumours in Bulgaria. IARC Scientific Publication, 1991; 115:83-87.
52. Petkova-Bocharova T, Castegnaro M. Ochratoxin A in human blood in relation to Balkan endemic nephropathy and urinary tract tumours in Bulgaria. IARC Scientific Publication, 1991; 115:135-137.
53. Petkova-Bocharova T, Castegnaro M, Pfohl-Leskowicz A, Garren L, Grosso F, Nikolov I, Vrabcheva T, Dragacci S, Chernozemsky IN. Analysis of ochratoxin A in serum and urine of inhabitants from an area with Balkan endemic nephropathy: A one-month follow-up study. Journal of Agricultural and Food Chemistry, 2003; 52(8):2404-2410.
54. Abid S, Hassen W, Achour A, Skhiri H, Maaroufi K, Ellouz F, Creppy E, Bacha H. Ochratoxin A and chronic human nephropathy in Tunisia: Is the situation endemic? Human and Experimental Toxicology, 2003; 22:77-84.
55. Breitholtz-Emanuelsson A, Minervini F, Hult K, Visconti A. Ochratoxin A in human serum samples collected in southern Italy from healthy individuals and individuals suffering from different kidney disorders. Natural Toxins, 1994; 2:366-370.
56. Hassen W, Abid S, Achour A, Creppy E, Bacha H. Ochratoxin A and beta2-microglobulinuria in healthy individuals and in chronic interstitial nephropathy patients in the centre of Tunisia: A hot spot of ochratoxin A exposure. Toxicology, 2004; 199:185-193.
57. Jimenez AM, Lopez de Cerain A, Gonzalez-Penas E, Bello J, Betebeder AM, Creppy EE. Exposure to ochratoxin A in Europe: Comparison with a region of northern Spain. Journal of Toxicology-Toxin Reviews, 1998; 17:479-491.
58. Khalef A, Zidane C, Charef A, Gharbi A, Tadjerouna M, Betbeder AM, Creppy EE. Ochratoxicose humaine en algerie. Pp. 167-174 in Creppy EE, Castegnaro M, Dirheimer G (eds). Human Ochratoxicosis and its Pathologies. France: Montrouge, 1993.
59. Malir F, Brndiar M, Roubal T, Severa J, Fixa P, Kacerovsky J, Zahradnik J, Osterreicher J, Knizek H, Cerna M. A study of the accumulation of ochratoxin A OTA in patients with chronic renal insufficiency (CHRI) in the Czech Republic. Mycotoxin Research, 2001; 17:39-44.
60. Malir F, Roubal T, Brndiar M, Osterreicher J, Severa J, Knizek H, Kacerovsky J, Tmejova M, Bebeder AM, Baudrimont I, Creppy EE. Ochratoxin A in the Czech Republic. Journal of Toxicology-Toxin Reviews, 2001; 20:261-274.
61. Ozcelik N, Kosar A, Sosal D. Ochratoxin A in human serum samples collected in Isparta-Turkey from healthy individuals and individuals suffering from different urinary disorders. Toxicology Letters, 2001; 121:9-13.
62. Voo S, Drugarin D, Biriescu A, Margineanu F, Olariu RT, Koreck IA. Ochratoxin A serum levels in patients with Balkan nephropathy. Central European Journal of Occupational and Environmental Medicine, 2002; 8:178-182.
63. Benyamin RM, Wafai Y, Salem MR, Joseph NJ. Two-handed mask ventilation of the difficult airway by a single individual. Anesthesiology, 1998; 88(4):1134.
64. Scott P. Biomarkers of human exposure to ochratoxin A. Food Additives and Contaminants, 2005; Supp 1:99-107.
65. Gilbert J, Brereton P, MacDonald S. Assessment of dietary exposure to ochratoxin A in the UK using a duplicate diet approach and analysis of urine and plasma samples. Food Additives & Contaminants, 2001; 18:1088-1093.
66. Grollman AP, Jelakovic B. Role of environmental toxins in endemic (Balkan) nephropathy. October 2006, Zagreb, Croatia. Journal of the American Society of Nephrology, 2007; 18(11):2817-2823.
67. Turesky RJ. Perspective: Ochratoxin A is not a genotoxic carcinogen. Chemical Research in Toxicology, 2005; 18(7):1082-1090.
68. Bui-Klimke TR, Wu F. Ochratoxin A and human health risk: A review of the evidence. Critical Reviews in Food Science and Nutrition, 2014 (in press). DOI:10.1080/10408398.2012.724480.
69. Grollman AP, Scarborough J, Jelaković B. Aristolochic acid nephropathy: An environmental and iatrogenic disease. Pp. 211-227 in CF James (ed). Advances in Molecular Toxicology, Vol. 3. Oxford, UK: Elsevier, 2009.
70. Vanherweghem JL, Tielemans C, Abramowicz D, Depierreux M, Vanhaelen-Fastre R, Vanhaelen M, Dratwa M, Richard C, Vandervelde D, Verbeelen D, Jadoul M. Rapidly progressive interstitial renal fibrosis in young women: Association with slimming regimen including Chinese herbs. Lancet, 1993; 341(8842):387-391.
71. Arlt VM, Stiborova M, Schmeiser HH. Aristolochic acid as a probable human cancer hazard in herbal remedies: A review. Mutagenesis, 2002; 17(4):265-277.
72. Cosyns JP, Dehoux JP, Guiot Y, Goebbels RM, Robert A, Bernard AM, van Ypersele de Strihou C. Chronic aristolochic acid toxicity in rabbits: A model of Chinese herbs nephropathy? Kidney International, 2001; 59(6):2164-2173.
73. Hranjec T, Kovac A, Kos J, Mao W, Chen JJ, Grollman AP, Jelakovic B. Endemic nephropathy: The case for chronic poisoning by aristolochia. Croatian Medical Journal, 2005; 46(1):116-125.
74. Bradford-Hill AB. The environment and disease: Association or causation? Proceedings of the Royal Society of Medicine, 1965; 58:295-300.
75. Rhomberg LR, Bailey LA, Goodman JE. Hypothesis-based weight of evidence: A tool for evaluating and communicating uncertainties and inconsistencies in the large body of evidence in proposing a carcinogenic mode of action-naphthalene as an example. Critical Reviews in Toxicology, 2010; 40(8):671-696.
76. Perrio M, Voss S, Shakir SA. Application of the Bradford Hill criteria to assess the causality of cisapride-induced arrhythmia: A model for assessing causal association in pharmacovigilance. Drug Safety, 2007; 30(4):333-346.
77. Uzoigwe JC, Khaitsa ML, Gibbs PS. Epidemiological evidence for mycobacterium avium subspecies paratuberculosis as a cause of Crohn's disease. Epidemiology & Infection, 2007; 135(7):1057-1068.
78. Cox L. Improving causal inferences in risk analysis. Risk Analysis, 2013; 33(10):1762-1771.
79. Radovanovic Z. Aetiology of Balkan nephropathy: A reappraisal after 30 years. European Journal of Epidemiology, 1989; 5:37-377.
80. Stefanovic V, Polenakovic M. Fifty years of research in Balkan endemic nephropathy: Where are we now? Nephron Clinical Practice, 2009; 112(2):c51-c56.
81. Ceovic S, Hrabar A, Radonic M. An etiological approach to Balkan endemic nephropathy based on the investigation of two genetically different populations. Nephron, 1985; 40(2):175-179.
82. Shibutani S, Suzuki N, Fernandes A, Leko N, Jelakovic B, Grollman AP. Balkan endemic nephropathy: A preventable environmental disease [abstract]. Cancer Epidemiology, Biomarkers & Prevention, 2005; 14:2717S.
83. Kohara A, Suzuki T, Honma M, Ohwada T, Hayashi M. Mutagenicity of aristolochic acid in the lambda/lacz transgenic mouse (mutamouse). Mutation Research, 2002; 515(1-2):63-72.
84. Lord GM, Cook T, Arlt VM, Schmeiser HH, Williams G, Pusey CD. Urothelial malignant disease and Chinese herbal nephropathy. Lancet, 2001; 358(9292):1515-1516.
85. Nortier JL, Martinez M-CM, Schmeiser HH, Arlt VM, Bieler CA, Petein M, Depierreux MF, De Pauw L, Abramowicz D, Vereerstraeten P, Vanherweghem J-L. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia Fangchi). New England Journal of Medicine, 2000; 342(23):1686-1692.
86. Lai MN, Wang SM, Chen PC, Chen YY, Wang JD. Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. Journal of the National Cancer Institute, 2010; 102(3):179-186.
87. Jelakovic B, Karanovic S, Vukovic-Lela I, Miller F, Edwards KL, Nikolic J, Tomic K, Slade N, Brdar B, Turesky RJ, Stipancic Z, Dittrich D, Grollman AP, Dickman KG. Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid. Kidney International, 2012; 81:559-567.
88. Pfohl-Leszkowicz A, Grosse Y, Castegnaro M, Nicolov IG, Chernozemsky IN, Bartsch H, Betbeder AM, Creppy EE, Dirheimer G. Ochratoxin A-related DNA adducts in urinary tract tumours of Bulgarian subjects. IARC Scientific Publication, 1993; 124:141-148.
89. Castegnaro M, Maru V, Petkova-Bocharova T, Nikolov I, Bartsch H. Concentrations of ochratoxin A in the urine of endemic nephropathy patients and controls in Bulgaria: Lack of detection of 4-hydroxyochratoxin a. IARC Scientific Publication, 1991; 115:165-169.
90. Vrabcheva T, Usleber E, Dietrich R, Martlbauer E. Co-occurrence of ochratoxin A and citrinin in cereals from Bulgarian villages with a history of Balkan endemic nephropathy. Journal of Agricultural and Food Chemistry, 2000; 48(6):2483-2488.
91. Phillips DH, Arlt VM. The 32p-postlabeling assay for DNA adducts. Nature Protocols, 2007; 2(11):2772-2781.
92. Uzelac-Keserovic B, Spasic P, Bojanic N, Dimitrijevic J, Lako B, Lepsanovic Z, Kuljic-Kapulica N, Vasic D, Apostolov K. Isolation of a coronavirus from kidney biopsies of endemic Balkan nephropathy patients. Nephron, 1999; 81(2):141-145.
93. Gautier J, Richoz J, Welti D, Markovic J. Metabolism of ochratoxin A: Absence of formation of genotoxic derivatives by human and rat enzymes. Chemical Research in Toxicology, 2000; 14:34-45.
94. Vanherweghem JL, Depierreux M, Tielemans C, Abramowicz D, Dratwa M, Jadoul M, Richard C, Vandervelde D, Verbeelen D, Vanhaelen-Fastre R, et al. Rapidly progressive interstitial renal fibrosis in young women: Association with slimming regimen including Chinese herbs. Lancet, 1993; 341(8842):387-391.
95. Guh JY, Chen HC, Tsai JF, Chuang LY. Herbal therapy is associated with the risk of CKD in adults not using analgesics in Taiwan. American Journal of Kidney Diseases, 2007; 49(5):626-633.
96. Hsieh SC, Lin IH, Tseng WL, Lee CH, Wang JD. Prescription profile of potentially aristolochic acid containing Chinese herbal products: An analysis of national health insurance data in Taiwan between 1997 and 2003. CORD Conference Proceedings, 2008; 3:13.
97. Vanherweghem JL. Aristolochia SP and chronic interstitial nephropathies in Indians. Lancet, 1997; 349(9062):1399.
98. Ivic M. [Etiology of endemic nephropathy]. Lijec Vjesn, 1969; 91(12):1273-1281.
99. Mengs U, Lang W, Poch J-A. The carcinogenic action of aristolochic acid in rats. Archives of Toxicology, 1982; 57:107-119.
100. Mengs U. On the histopathogenesis of rat forestomach carcinoma caused by aristolochic acid. Archives of Toxicology, 1983; 52(3):209-220.
101. Mengs U. Tumour induction in mice following exposure to aristolochic acid. Archives of Toxicology, 1988; 61(6):504-505.
102. Mengs U, Stotzem C. Renal toxicity of aristolochic acid in rats as an example of nephrotoxicity testing in routine toxicology. Archives of Toxicology, 1993; 67(5):307-311.
103. Cosyns J, Goebbels R-M, Liberton V, Schmeiser H, Bieler C, Bernard A. Chinese herbs nephropathy-associated slimming regimen induces tumours in the forestomach but no interstitial nephropathy in rats. Archives of Toxicology, 1998; 72:738-748.
104. Debelle FD, Nortier JL, De Prez EG, Garbar CH, Vienne AR, Salmon IJ, Deschodt-Lanckman MM, Vanherweghem JL. Aristolochic acids induce chronic renal failure with interstitial fibrosis in salt-depleted rats. Journal of the American Society of Nephrology, 2002; 13(2):431-436.
105. Chen M, Su M, Zhao L, Jiang J, Liu P, Cheng J, Lai Y, Liu Y, Jia W. Metabonomic study of aristolochic acid-induced nephrotoxicity in rats. Journal of Proteomic Research, 2006; 5(4):995-1002.
106. Chen SM, Fan MY, Tseng CC, Ho Y, Hsu KY. Pharmacokinetics and nephrotoxicity of aristolochic acid in rabbits. Toxicon, 2007; 50(2):180-188.
107. Yang HY, Zheng XH, Du Y, Chen Z, Zhu DY, Lou YJ. Kinetics of aristolochic acid i after oral administration of radix aristolochiae or guanxinsuhe preparation in canines. Journal of Ethnopharmacology, 2011; 135(2):569-574.
108. Liu M, Maruyama S, Mizuno M, Morita Y, Hanaki S, Yuzawa Y, Matsuo S. The nephrotoxicity of aristolochia manshuriensis in rats is attributable to its aristolochic acids. Clinical and Experimental Nephrology, 2003; 7:186-194.
109. Sato N, Takahashi D, Chen SM, Tsuchiya R, Mukoyama T, Yamagata S, Ogawa M, Yoshida M, Kondo S, Satoh N, Ueda S. Acute nephrotoxicity of aristolochic acids in mice. Journal of Pharmacy and Pharmacology, 2004; 56(2):221-229.
110. Hwang MS, Park MS, Moon JY, Lee JS, Yum YN, Yoon E, Lee H, Nam KT, Lee BM, Kim SH, Yang KH. Subchronic toxicity studies of the aqueous extract of aristolochiae fructus in Sprague-Dawley rats. Journal of Toxicology and Environmental Health, Part A, 2006; 69(24):2157-2165.
111. Wang HL, Zhang JY. [Aristolochic acid induces renal tubular injury and inhibits expression of bone morphogenetic protein-7 mRNA in renal tissue of rats]. Zhong Xi Yi Jie He Xue Bao, 2008; 6(5):501-507.
112. Lou Y, Li J, Lu Y, Wang X, Jiao R, Wang S, Kong L. Stolochic acid-induced destruction of organic ion transporters and fatty acid metabolic disorder in the kidney of rats. Toxicology Letters, 2011; 201(1):72-79.
113. Cui M, Liu ZH, Qiu Q, Li H, Li LS. Tumour induction in rats following exposure to short-term high dose aristolochic acid i. Mutagenesis, 2005; 20(1):45-49.
114. Mei N, Arlt VM, Phillips DH, Heflich RH, Chen T. DNA adduct formation and mutation induction by aristolochic acid in rat kidney and liver. Mutation Research, 2006; 602(1-2):83-91.
115. Zhou L, Fu P, Huang XR, Liu F, Lai KN, Lan HY. Activation of p53 promotes renal injury in acute aristolochic acid nephropathy. Journal of the American Society of Nephrology, 2010; 21(1):31-41.
116. Wang Y, Arlt VM, Roufosse CA, McKim KL, Myers MB, Phillips DH, Parsons BL. ACB-PCR measurement of h-ras codon 61 CAA->CTA mutation provides an early indication of aristolochic acid i carcinogenic effect in tumor target tissues. Environmental and Molecular Mutagenesis, 2012; 53(7):495-504.
117. Wang Y, Meng F, Arlt VM, Mei N, Chen T, Parsons BL. Aristolochic acid-induced carcinogenesis examined by ACB-PCR quantification of h-ras and k-ras mutant fraction. Mutagenesis, 2011; 26(5):619-628.
118. Wafa EW, Yahya RS, Sobh MA, Eraky I, El-Baz M, El-Gayar HA, Betbeder AM, Creppy EE. Human ochratoxicosis and nephropathy in Egypt: A preliminary study. Human and Experimental Toxicology, 1998; 17:124-129.
119. Godin M, Francois A, Le Roy M, Morin J-P, Creppy E, Hemet J, Fillastre JP. Karyomegalic interstitial nephritis. American Journal of Kidney Diseases, 1996; 27:166.
120. Duarte SC, Pena A, Lino CM. Ochratoxin A in Portugal: A review to assess human exposure. Toxins (Basel), 2010; 2(6):1225-1249.
121. Fazekas B, Tar A, Kovacs M. Ochratoxin A content of urine samples of healthy humans in Hungary. Acta Veterinaria Hungarica, 2005; 53(1):35-44.
122. Pascale M, Visconti A. Rapid method for the determination of ochratoxin A in urine by immunoaffinity column clean-up and high performance liquid chromatography. Mycopathologia, 2000; 152:91-95.
123. Manev H, Gancheva E, Yanakieva M. The etiology and epidemiology of the leptospirosis in Bulgaria. Archives Roumaines de Pathologie Experimentale et de Microbiologie, 1987; 46(3):233-239.
124. Russev H. Attempts to isolate in tissue cultures a cytopathogenic virus from the blood serum of cattles in Beli Izvor. Endemic Nephritis in Bulgaria, 1960:187-190.
125. Cosyns JP, Jadoul M, Squifflet JP, Van Cangh PJ, van Ypersele de Strihou C. Urothelial malignancy in nephropathy due to Chinese herbs. Lancet, 1994; 344(8916):188.
126. Kuiper-Goodman T, Hilts C, Billiard SM, Kiparissis Y, Richard IK, Hayward S. Health risk assessment of ochratoxin A for all age-sex strata in a market economy. Food Additives and Contaminants, 2010; 27(2):212-240.
127. Nikolov IG, Petkova-Bocharova D, Castegnaro M, Pfohl-Leskowicz A, Gill C, Day N, Chernozemsky IN. Molecular and epidemiological approaches to the etiology of urinary tract tumors in an area with Balkan endemic nephropathy. Journal of Environmental Pathology, Toxicology and Oncology, 1996; 15:201-207.
128. Mantle P, Kulinskaya E. Lifetime, low-dose ochratoxin A dietary study on renal carcinogenesis in male Fischer rats. Food Additives & Contaminants Part A Chemistry, Analysis, Control, Exposure & Risk Assessment, 2010; 27(11):1566-1573.
129. Goncalves-de-Albuquerque CF, Burth P, Silva AR, Younes-Ibrahim M, Castro-Faria-Neto HC, Castro-Faria MV. Leptospira and inflammation. Mediators of Inflammation, 2012; 2012:317950.
130. Nielsen T, Jorgensen HE, Larsen JC, Poulsen M. City air pollution of polycyclic aromatic hydrocarbons and other mutagens: Occurrence, sources and health effects. Science of the Total Environment, 1996; 189-190:41-49.
131. van der Hoek L. Human coronaviruses: What do they cause? Antiviral Therapy, 2007; 12(4 Pt B):651-658.
132. Chernozemsky IN, Stoyanov IS, Petkova-Bocharova TK, Nikolov IG, Draganov IG, Stoichev I, Tanchev Y, Naidenov D, Kalcheva ND. Geographic correlation between the occurrence of endemic nephropathy and urinary tract tumours in Vratza district, Bulgaria. International Journal of Cancer, 1977; 19:1-11.
133. Martinez MC, Nortier J, Vereerstraeten P, Vanherweghem JL. Progression rate of Chinese herb nephropathy: Impact of Aristolochia Fangchi ingested dose. Nephrology Dialysis Transplantation, 2002; 17(3):408-412.
134. Munro IC, Moodie CA, Kuiper-Goodman T, Scott PM, Grice HC. Toxicologic changes in rats fed graded dietary levels of ochratoxin A. Toxicology and Applied Pharmacology, 1974; 28(2):180-188.
135. Berndt WO, Hayes AW. In vivo and in vitro changes in renal function caused by ochratoxin A in the rat. Toxicology, 1979; 12(1):5-17.
136. Suzuki S, Kozuka Y, Satoh T, Yamazaki M. Studies on the nephrotoxicity of ochratoxin A in rats. Toxicology and Applied Pharmacology, 1975; 34(3):479-490.
137. Kitchen DN, Carlton WW, Hinsman EJ. Ochratoxin A and citrinin induced nephrosis in beagle dogs. III. Terminal renal ultrastructural alterations. Veterinary Pathology, 1977; 14(4):392-406.
138. Kitchen DN, Carlton WW, Tuite J. Ochratoxin A and citrinin induced nephrosis in beagle dogs. II. Pathology. Veterinary Pathology, 1977; 14(3):261-272.
139. Kitchen DN, Carlton WW, Tuite J. Ochratoxin A and citrinin induced nephrosis in beagle dogs. I. Clinical and clinicopathological features. Veterinary Pathology, 1977; 14(2):154-172.
140. Krogh P, Axelsen NH, Elling F, Gyrd-Hansen N, Hald B, Hyldgaard-Jensen J, Larsen AE, Madsen A, Mortensen HP, Moller T, Petersen OK, Ravnskov U, Rostgaard M, Aalund O. Experimental porcine nephropathy. Changes of renal fucntion and structure induced by ochratoxin A contaminated feed. Acta Pathologica Microbiologica Immunologica Scandinavica, 1974; 246:1-21.
141. Gibson RM, Bailey CA, Kubena LF, Huff WE, Harvey RB. Impact of l-phenylalanine supplementation on the performance of three-week-old broilers fed diets containing ochratoxin A. 1. Effects on body weight, feed conversion, relative organ weight, and mortality. Poultry Science, 1990; 69(3):414-419.
142. Kanisawa M, Suzuki S. Induction of renal and hepatic tumors in mice by ochratoxin A; A mycotoxin. Gann, 1978; 69:599-600.
143. Rao C. Obstructive uropathy in group caged male b6c3f1 mice on a 24-month carcinogenicity study (letter). Laboratory Animal Science, 1987; 37:8-9.
144. Mally A. Ochratoxin A and mitotic disruption: Mode of action analysis of renal tumor formation by ochratoxin A. Toxicological Sciences, 2012; 127(2):315-330.
145. Asha S, Girija D. Benzo[a]pyrene induced liver and kidney cancer in Swiss albino mice. Research in Pharmacy, 2011; 1(4):22-27.
146. Bosetti C, Boffetta P, La Vecchia C. Occupational exposures to polycyclic aromatic hydrocarbons, and respiratory and urinary tract cancers: A quantitative review to 2005. Annals of Oncology, 2007; 18(3):431-446.
147. Shen CH, Wu JD, Hsu CD, Jou YC, Lin CT, Wang M, Wu SF, Chan MW, Chiang MK, Fang CY, Chang D. The high incidence of jc virus infection in urothelial carcinoma tissue in Taiwan. Journal of Medical Virology, 2011; 83(12):2191-2199.
148. Pfohl-Leszkowicz A, Chakor K, Creppy EE, Dirheimer G. DNA adduct formation in mice treated with ochratoxin A. IARC Scientific Publication, 1991; 115:245-253.
149. Pfohl-Leszkowicz A, Grosse Y, Kane A, Creppy EE, Dirheimer G. Differential DNA adduct formation and disappearance in three mouse tissues after treatment with the mycotoxin ochratoxin A. Mutation Research, 1993; 289(2):265-273.
150. Wang M, Nishikawa A, Chung FL. Differential effects of thiols on DNA modifications via alkylation and michael addition by alpha-acetoxy-n-nitrosopyrrolidine. Chemical Research in Toxicology, 1992; 5(4):528-531.
151. Gautier JC, Holzhaeuser D, Markovic J, Gremaud E, Schilter B, Turesky RJ. Oxidative damage and stress response from ochratoxin A exposure in rats. Free Radical Biology and Medicine, 2001; 30(10):1089-1098.
152. Olivier M, Hollstein M, Schmeiser HH, Straif K, Wild CP. Upper urinary tract urothelial cancers: Where it is A:T. Nature Reviews Cancer, 2012; 12(8):503-504.
153. Grollman AP. Aristolochic acid nephropathy: Harbinger of a global iatrogenic disease. Environmental and Molecular Mutagenesis, 2013; 54(1):1-7.
154. Hofler M. The Bradford Hill considerations on causality: A counterfactual perspective. Emerging Themes in Epidemiology, 2005; 2:11.
155. Domijan AM, Peraica M, Markov K, Fuchs R. Urine ochratoxin A and sphinganine/sphingosine ratio in residents of the endemic nephropathy area in Croatia. Arh Hig Rada Toksikol, 2009; 60(4):387-393.
156. Georgescu L, Litvac B, Diosi P, Plavosin L, Herzog G. Letter: Viruses in endemic (Balkan) nephropathy. Lancet, 1976; 1(7968):1086.
157. Georgescu L, Diosi P, Butiu I, Plavosin L, Herzog G. Porcine coronavirus antibodies in endemic (Balkan) nephropathy. Lancet, 1978; 1(8056):163.
158. Pfohl-Leszkowicz A, Tozlovanu M, Manderville R, Peraica M, Castegnaro M, Stefanovic V. New molecular and field evidences for the implication of mycotoxins but not aristolochic acid in human nephropathy and urinary tract tumor. Molecular Nutrition & Food Research, 2007; 51:1131-1146.